JUL 27 2026
Otsuka Pharmaceutical — SIMTRIYO (centanafadine)
for ADHD
About
SIMTRIYO (centanafadine) is a treatment for attention deficit hyperactivity disorder (ADHD), a condition that impairs focus, increases restlessness, and can disrupt emotional control. The drug works by adjusting the levels of key brain chemicals involved in attention and behavior. This mechanism may help manage the core symptoms of inattention and hyperactivity in adults, including those who also experience anxiety.
Pivotal trial
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on SIMTRIYO
- Otsuka reports expanded Phase IIIb results for Simtriyo in adult ADHD - Clinical Trials Arena
- Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026 - BioSpace
- Centanafadine Receives FDA Approval for the Treatment of ADHD - ADDitude
- Physician Views Results: Simtriyo draws interest despite Schedule II wildcard - FirstWord
- Will Newly Approved Centanafadine Transform ADHD Care? - physiciansweekly.com